145 related articles for article (PubMed ID: 18473991)
1. Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide.
Doggrell SA
Rev Recent Clin Trials; 2007 Jan; 2(1):77-84. PubMed ID: 18473991
[TBL] [Abstract][Full Text] [Related]
2. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Reuter H; Erdmann E
Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
4. [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Kress S
Dtsch Med Wochenschr; 2010 May; 135(18):907-10. PubMed ID: 20425675
[TBL] [Abstract][Full Text] [Related]
5. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Iltz JL; Baker DE; Setter SM; Keith Campbell R
Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
[TBL] [Abstract][Full Text] [Related]
6. Is exenatide advancing the treatment of type 2 diabetes?
Doggrell SA
Expert Opin Pharmacother; 2006 Jan; 7(1):109-12. PubMed ID: 16370928
[TBL] [Abstract][Full Text] [Related]
7. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.
McCall AL; Cox DJ; Brodows R; Crean J; Johns D; Kovatchev B
Diabetes Technol Ther; 2009 Jun; 11(6):339-44. PubMed ID: 19459761
[TBL] [Abstract][Full Text] [Related]
8. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
[TBL] [Abstract][Full Text] [Related]
9. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
Cvetković RS; Plosker GL
Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
Nauck MA; Meier JJ
Nat Rev Endocrinol; 2011 Apr; 7(4):193-5. PubMed ID: 21326278
[No Abstract] [Full Text] [Related]
11. Exenatide.
Keating GM
Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
[TBL] [Abstract][Full Text] [Related]
12. [Glucagon-like peptide 1 (GLP-1)].
Parhofer KG
MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
[TBL] [Abstract][Full Text] [Related]
13. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
Glass LC; Qu Y; Lenox S; Kim D; Gates JR; Brodows R; Trautmann M; Bergenstal RM
Curr Med Res Opin; 2008 Mar; 24(3):639-44. PubMed ID: 18218179
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
16. Exenatide: its position in the treatment of type 2 diabetes.
Guerci B; Martin CS
Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom.
Woehl A; Evans M; Tetlow AP; McEwan P
Cardiovasc Diabetol; 2008 Aug; 7():24. PubMed ID: 18694484
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
19. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B
Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
[TBL] [Abstract][Full Text] [Related]
20. Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
; Probstfield JL; Hirsch I; O'Brien K; Davis B; Bergenstal R; Kingry C; Khakpour D; Pressel S; Branch KR; Riddle M
Diabetes Care; 2015 Aug; 38(8):1558-66. PubMed ID: 26068865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]